BioLife Solutions Announces Preliminary 2017 Revenue Increase of 34% to $11 Million
Q4 2017 Preliminary Revenue Reaches Record $3.1 Million, up 39% over Q4 2016 On January 4, 2018 BioLife Solutions Inc. (NASDAQ: BLFS) (“BioLife”), the leading developer, manufacturer and marketer of proprietary clinical-grade cell and tissue hypothermic storage and cryopreservation freeze media, announced preliminary Q4 and full year 2017 revenue and provided additional operational updates and financial guidance for 2018. […]
BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics
On December 13, 2017 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media (“BioLife” or the “Company”), announced that it has executed an agreement to supply its CryoStor® cell freeze media and HypoThermosol® cell storage and shipping media to Iovance Biotherapeutics, Inc. (“Iovance”) (NASDAQ: IOVA). Iovance is […]
Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea
Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea A huge congratulations to BioLife customer TissueGene / Kolon Life Science on their first patient use of CryoStor – powered Invossa, a novel cell-mediated therapy for degenerative arthritis. Invossa is the world’s first gene therapy for treating osteoarthritis of the knee, in which the cartilage that cushions […]
BioLife Solutions to Present at September Investment Conferences
BioLife Solutions Inc. (NASDAQ: BLFS) announces that Mike Rice, President and CEO, will be presenting at two investment conferences in September: Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12th, at 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference is being held at the New York Palace Hotel in New York […]
BioLife Solutions Executes Supply Agreement with Celyad
BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers Proprietary Clinical Grade Cell Freeze Media Enables Long-Term Storage and Distribution of Engineered Cell-Based Therapies BioLife is pleased to announce that it has executed a long term supply agreement with NASDAQ-listed Celyad, […]
BioLife Solutions Executes 10 Year Supply Agreement with Kite Pharma for CryoStor® Use in CAR T Cell Therapies
BioLife and Kite Pharma are pleased to announce that they have entered into a 10 year supply agreement for BioLife’s CryoStor clinical grade freeze media for cells and tissues, which is embedded in Kite’s manufacturing process for KTE-C19, a CAR T cell therapy. Kite Pharma is currently in four clinical trials for various cancers. Marc […]